Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Aavantgarde, Aminex, BMS, Calico, Nacuity, Prothena, Taysha Gene Therapies.
Biopharma financings from January through September 2025 totaled $47.1 billion, a sharp decline from 2024’s $86.7 billion during the same period and well below the highs of 2020 and 2021. The slowdown was driven largely by weaker follow-on activity, which brought in $12.9 billion compared to more than $40 billion last year.
RSS
